Natco Pharma Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

The company had received Central Drugs Standard Control Organisation (CDSCO) approval to manufacture and market generic Semaglutide in India in February?26 for multi dose vials and pen device based on the clinical comparison study.

The drug is used for the treatment of adults suffering from inadequately controlled Type 2 diabetes, along with diet and exercise.

NATCO plans to launch Semaglutide injection in the form of multi dose vials of strengths 2mg/1.5ml, 4mg/3ml and 8mg/3ml under the brand names SEMANAT and SEMAFULL. Multi dose vials will be launched at MRP of Rs 1,290 per month for 2 mg/1.5ml & 4mg/3ml and MRP of Rs 1,750 for 8mg/3ml.

Pen device will be priced at MRP of Rs 4,000, Rs 4,200 and Rs 4,500 per month for the strengths 2mg/1.5ml, 4mg/3ml and 8mg/3ml respectively. Pen device is expected to be launched in April?26.

The company said that it is the first company to offer Semaglutide in the vial dosage form. It is the most affordable GLP-1 currently in the Indian market as it is approximately 70% cheaper in cost than the pen device and 90% cheaper than the price of the innovator?s brand.

NATCO Pharma, headquartered in Hyderabad, India, develops, manufactures, and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients, and crop protection products.

The company?s consolidated net profit jumped 13.9% to Rs 151.50 crore on a 36.3% increase in revenue from operations to Rs 647.30 crore in Q3 FY26 over Q3 FY25.

Powered by Capital Market - Live News

NATCO Pharma announced the launch of Semaglutide Injection (multi dose vials) in India market tomorrow on Day 1 of patent expiry.

NATCO received Central Drugs Standard Control Organisation (CDSCO) approval to manufacture and market generic Semaglutide in India in February'26 for multi dose vials and pen device based on the clinical comparison study.

 Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise.

NATCO plans to launch Semaglutide injection in the form of multi dose vials of strengths 2mg/1.5ml, 4mg/3ml and 8mg/3ml under the brand names SEMANATTM and SEMAFULLTM. Multi dose vials will be launched at MRP of INR 1,290 per month for 2 mg/1.5ml & 4mg/3ml and MRP of INR 1,750 for 8mg/3ml. Pen device will be priced at MRP of INR 4,000, INR 4,200 and INR 4,500 per month for the strengths 2mg/1.5ml, 4mg/3ml and 8mg/3ml respectively. Pen device is expected to be launched in April'26.

NATCO is the first company to offer generic Semaglutide in multi dose vials with customised syringes. NATCO is also offering the product to third parties for co-marketing.

Powered by Capital Market - Live News

Natco Pharma will hold a meeting of the Board of Directors of the Company on 24 March 2026.

Powered by Capital Market - Live News

Pomalidomide Capsules, a thalidomide analogue, are indicated for the treatment of adult patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor, and have demonstrated disease progression on or within 60 days of completion of the last therapy.

The drug is also approved for AIDS-related Kaposi sarcoma after failure of highly active antiretroviral therapy (HAART), as well as for HIV-negative adult patients with Kaposi sarcoma. The product is available in 1 mg, 2 mg, 3 mg, and 4 mg strengths and is primarily distributed through specialty pharmacies and clinics.

NATCO said based on information made available by the U.S. Food and Drug Administration (FDA), it believes that it has 180 days of shared exclusivity. Pomalidomide Capsules 1 mg, 2 mg, 3 mg, and 4 mg had estimated sales of $3.2 billion in the U.S. for the 12 months ending September 2025, the company said, citing industry sales data.

Rajeev Nannapaneni, vice chairman and chief executive officer of NATCO Pharma, said, ?We are pleased to launch Pomalidomide Capsules in the U.S.; this further strengthens our oncology and specialty portfolio in the U.S. The launch highlights our commitment to our mission of making specialty medicines accessible to all the patients worldwide. We look forward to bringing more such complex and specialty products to the market in the coming years.?

NATCO Pharma, headquartered in Hyderabad, India, develops, manufactures, and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients, and crop protection products.

The company?s consolidated net profit jumped 13.9% to Rs 151.50 crore on a 36.3% increase in revenue from operations to Rs 647.30 crore in Q3 FY26 over Q3 FY25.

Powered by Capital Market - Live News